Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

[1]  F. Saad,et al.  Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer , 2006, Clinical Cancer Research.

[2]  L. Dogliotti,et al.  Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease , 2005, British Journal of Cancer.

[3]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Pinski,et al.  Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. , 2005, European journal of cancer.

[5]  F. Saad,et al.  Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. , 2005, Journal of the National Cancer Institute.

[6]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[7]  Gordon Johnston,et al.  Statistical Models and Methods for Lifetime Data , 2003, Technometrics.

[8]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. U. Uyl‐de Groot,et al.  Costs of prostate cancer, metastatic to the bone, in the Netherlands. , 2003, European urology.

[10]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[11]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Resnick,et al.  Skeletal fractures negatively correlate with overall survival in men with prostate cancer. , 2002, The Journal of urology.

[13]  C. Catton,et al.  A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma , 2001, Cancer.

[14]  P. Garnero.  Markers of bone turnover in prostate cancer. , 2001, Cancer treatment reviews.

[15]  P. Delmas,et al.  Markers of bone turnover in bone metastases , 2000, Cancer.

[16]  S. Cerutti,et al.  Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. , 1999, Clinical chemistry.

[17]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[18]  P. Grambsch,et al.  Goodness-of-fit and diagnostics for proportional hazards regression models. , 1995, Cancer treatment and research.

[19]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[20]  S. Posen,et al.  The measurement of serum alkaline phosphatase in clinical medicine. , 1981, Advances in clinical chemistry.